Last reviewed · How we verify
monoclonal antibody BEC2
BEC2 is a monoclonal antibody that targets GD3 ganglioside on tumor cell surfaces to trigger immune-mediated destruction of cancer cells.
BEC2 is a monoclonal antibody that targets GD3 ganglioside on tumor cell surfaces to trigger immune-mediated destruction of cancer cells. Used for Melanoma (advanced or metastatic), Small cell lung cancer.
At a glance
| Generic name | monoclonal antibody BEC2 |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Drug class | monoclonal antibody |
| Target | GD3 ganglioside |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BEC2 recognizes and binds to GD3, a glycolipid antigen expressed on melanoma and other cancer cells. By coating tumor cells with antibody, BEC2 facilitates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), recruiting the patient's immune system to eliminate malignant cells. It has been investigated as both a therapeutic agent and as part of cancer vaccine strategies.
Approved indications
- Melanoma (advanced or metastatic)
- Small cell lung cancer
Common side effects
- Infusion-related reactions
- Fever
- Chills
- Fatigue
Key clinical trials
- Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer (PHASE3)
- Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (PHASE3)
- Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |